NXL (37) VBIO (44) NDRA (48) IRIX (34) ⌘ Pro Terminal →

Nuwellis Inc. (NUWE) — RQD Stock Rating Cockpit

$5.78 +2.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.79

Nuwellis Inc. (NUWE) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.79 (+0.19%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUWE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY NUWE SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 89.8 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.68-19.1% Next Q

Q2 (-2Q)

Grade D$0.55-10.9% Next Q

Q3 (-1Q)

Grade D$0.49+1079.6% Next Q

Current

Grade D$5.78-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NUWE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NUWE currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($6.07) forces dealer call-delta covering toward $1,633.90.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUWE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NUWE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERBOUGHT (>70)

89.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $3$5.78H: $1,556

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NUWE

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 62.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (35)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

17/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like NUWE

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NUWE)

✓Walkthrough of NUWE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NUWE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -85.39%▲ RESISTANCE BREAKOUT

2026-10-30O $5.59H $6.10L $5.20C $5.78VOL 305.5K

RES: $-2.90SUP: $0.25SMA50: $1.15SMA200: $26.94

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NUWE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NUWE Butterfly Map → + Track NUWE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -5.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NUWE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NUWE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NUWE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUWE)

Health Care Rank #494 of 1016 ⚔️ NXL vs NUWE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NUWE vs. NXL, VBIO, NDRA, IRIX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nuwellis Inc. (NUWE) ranks #494 by composite RQD confidence (45/100, grade D) and #992 by equity capitalization ($2.3M). Within this direct 5-issuer industry benchmark cohort, NUWE leads on earnings valuation at N/A trailing P/E, while NUWE leads on capital efficiency and profitability with -35.0% ROIC and 62.0% gross margin. NDRA currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with NUWE at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NUWE ACTIVE Nuwellis Inc.	D	45/100	—	62.0%	-35.0%	+2.12%	$2.3M	Benchmark Subject
NXL Nexalin Technology Inc.	D-	37/100	—	79.7%	-35.0%	0.00%	$1.9M	/nxl-vs-nuwe →
VBIO Valion Bio Inc.	D	44/100	—	—	-35.0%	-9.13%	$1.3M	/vbio-vs-nuwe →
NDRA ENDRA Life Sciences Inc.	D	48/100	—	—	-35.0%	+2.95%	$7.3M	/ndra-vs-nuwe →
IRIX IRIDEX Corporation	E	34/100	—	36.5%	-35.0%	-2.92%	$12.7M	/irix-vs-nuwe →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001506492

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuwellis Inc. (NUWE) reported GAAP revenue of $8.3M (-5.4% vs. FY2024 revenue of $8.7M , and -6.7% cumulative change since FY2023) , GAAP net income of -$17.5M, operating cash flow of -$10.8M, and free cash flow of -$10.9M (-12.9% YoY). On the balance sheet, NUWE closed FY2025 with $6.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$8.3M	-$17.5M	-$10.8M	-$10.9M	$6.1M	—
FY2024 (FY)	2024-12-31	$8.7M	-$11.2M	-$9.6M	-$9.7M	$9.9M	—
FY2023 (FY)	2023-12-31	$8.9M	-$20.2M	-$17.9M	-$17.9M	—	—

3. NUWE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NUWE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nuwellis Inc. (NASDAQ: NUWE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $5.78 (+2.12% 1D, market cap $2.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NUWE ranks #494 in composite RQD confidence.

How does NUWE compare to NXL and VBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NUWE carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, NXL (Nexalin Technology Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M) and VBIO (Valion Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.3M). Among the 5-stock peer group, NUWE leads on earnings multiple (N/A) while NUWE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NUWE?

Per NUWE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001506492), Nuwellis Inc. generated $8.3M in revenue (-5.4% YoY), -$17.5M in net income, and -$10.9M in free cash flow against $6.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NUWE trading relative to its 50-day, 200-day, and 52-week technical levels?

NUWE last traded at $5.78 (+2.12% on volume of 14,746,763 shares), positioning the stock +402.61% above its 50-day simple moving average ($1.15) and -78.54% below its 200-day simple moving average ($26.94). Across its 52-week range of $2.52 to $1,556.10, NUWE sits at the 0.2% percentile with a 14-day RSI of 89.8 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.06 to $6.50).

NUWE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell NUWE stock right now?

Nuwellis Inc. (NUWE) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is NUWE's 12-month price target and RQD AI Jury consensus?

NUWE's 12-month base price target is $5.44 (range $4.24 to $1633.9), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: NUWE RQD Cockpit NUWE 12M Forecast NUWE Earnings & Move NUWE Dividends & DRIP NUWE Insiders & 13F NUWE Whale Options NUWE Profit Sankey NUWE News & Why